GOV Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelA consumables-driven model (disposable pods replaced regularly) creates predictable, repeat revenue and high lifetime customer value. This structural cash flow cadence supports durable sales visibility, recurring gross-margin contribution and easier planning for manufacturing and distribution investments.
Multi-year Revenue Scale And High Gross MarginsSustained rapid revenue growth alongside industry-leading gross margins signals structural competitiveness in product design and manufacturing. High margins provide operating leverage as scale grows, enabling reinvestment in R&D, commercial expansion and margin-resilient profitability over the medium term.
Strengthened Cash Generation And Balance SheetA turnaround from negative to multi-hundred-million FCF materially improves financial flexibility. Consistent free cash enables capex for capacity, selective buybacks and debt reduction, reducing leverage risk and giving management choices to support durable growth and withstand execution hiccups.
Bears Say
Product Safety CorrectionsLarge-scale corrections and reported serious adverse events impose direct remediation costs and elevate regulatory and reputational risk. Persistent or recurring manufacturing quality issues can erode provider/payer trust, complicate reimbursement, slow new customer adoption and increase ongoing compliance and quality-control expenses.
Retention Pressure From Type 2 MixA growing Type 2 customer segment can exhibit higher early attrition versus Type 1 users, reducing pods-per-patient lifetime. Structural declines in retention lower recurring revenue and weaken unit economics, requiring sustained investment in onboarding, education and care programs to preserve long-term refill volumes.
Capex Ramp Limits Near-term Free Cash Flow ExpansionPlanned manufacturing and automation investments are necessary for scale but compress near-term cash conversion. Flat FCF despite rapid revenue growth reduces optionality for accelerated deleveraging or additional shareholder returns, and raises execution risk if capacity investments lag demand or cost more than anticipated.
Insulet News
GOV FAQ
What was Insulet’s price range in the past 12 months?
Currently, no data Available
What is Insulet’s market cap?
Insulet’s market cap is CHF9.26B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Oct 29, 2026 which is in 85 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 05, 2026. The company reported CHF1.342 earnings per share for the quarter, beating the consensus estimate of CHF1.175 by CHF0.167.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.32.
How many shares outstanding does Insulet have?
Currently, no data Available
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of CHF1.342 in its last earnings report, beating expectations of CHF1.175. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in CH:GOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF179.03 (― Upside)
CHF179.03 (― Upside)
Blogger Sentiment
Bullish
CH:GOV Sentiment 82%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth CHF678.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-15.07%
Trailing 12-Months
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
GOV Company Deck
GOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: robust revenue growth (30% constant-currency company; 45% international), margin expansion, ~40% EPS growth, raised full-year guidance, product R&D progress (Libre 3 Plus integration, Omnipod 6, fully closed-loop type 2) and healthy cash generation and buybacks. Offsetting items were largely identifiable, management-described headwinds and investments — including a voluntary medical device correction with related costs (~$12M), excess & obsolescence charges during a product transition (impacting gross margin >150 bps), short-term seasonality affecting Q1 U.S. new customer starts, modest retention pressure as type 2 mix grows, and elevated interest/cost pressures. Overall, positives (strong growth, margin expansion, product pipeline, guidance raise and cash actions) materially outweigh the disclosed challenges, which management framed as manageable, partly one-time, or investments to support durable growth.View all CH:GOV earnings summariesGOV Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
GOV Stock 12 Month Forecast
Average Price Target
―Dexcom
―
Koninklijke Philips
―
Steris
―
Zimmer Biomet Holdings
―
Tandem Diabetes Care
―